2004
Aljada IS, Ramnath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, Khoury T, Loewen G, Slocum HK, Anderson TM, Bepler G, Tan D. Upregulation of the tissue inhibitor of metalloproteinase –1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol 22:3218-3229, 2004
Ammanamanchi S, Brattain MG. Restoration of TGF-â signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells. J Biol Chem 279(31):32620-32625, 2004
Ammanamanchi S, Tillekeratne MPM, Ko TC, Brattain MG. Endogenous control of cell cycle progression by autocrine TGF-b in breast cancer cells. Cancer Res. 64:2509-2515, 2004
Appendino G, Bettoni P, Noncovich A, Sterner O, Fontana G, Bombardelli E, Pera P, Bernacki RJ. Structure-activity relationships of ring C-secotaxoids. 1. Acylative modifications. J Nat Prod 67(2):184-188, 2004
Azrak RG, Cao S, Slocum HK, Toth K, Durrani FA, Yin M-G, Pendyala L, Zhang W, McLeod HL, Rustum YM. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 10:1121-1129, 2004
Azrak RG, Cao S, Slocum HK, Toth K, Durrani FA, Yin M-G, Pendyala L, Zhang W, McLeod HL, Rustum YM. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res. 10:1121-1129, 2004
Bai S, Goodrich DW. Different DNA lesions trigger distinct cell death responses in colon carcinoma HCT116 Cells. Mol Cancer Ther 3(5):613-619, 2004
Bateman NW, Tan D, Pestell RG, Black JD, Black AR. Intestinal tumor progression is associated with altered function of KLF5. J. Biol. Chem. 279:12093-12101, 2004
Berleth ES. Fanconi anemia pathway defects in neoplasia: Cause or effect? Cancer Biol Ther 3(6):538-539, 2004
Bernacki RJ, Pera P, Morazzoni P, Manzotti C, Riva A, Bombardelli E. Effect of silbin and docetael on LNCap prostate cell growth and total PSA levels. Eur J Cancer supplements 2:175, 2004
Bhattacharya A, Toth K, Mazurchuk R, Spernyak J, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, Rustum YM . Lack of microvessels in well differentiated regions of human head and neck squamous cell carcinoma A253 is associated with fMR imaging detectable hypoxia, limited drug delivery and resistance to irinotecan therapy. Clin Cancer Res. 20(23):8005-8017, 2004
Bihani T, Mason DX, Jackson T, Lin A. Differential oncogenic Ras signaling and senescence in tumor cells. Cell Cycle 3:9:88-94, 2004
Brooks TA, Kennedy DR, Gruol DJ, Ojima I, Baer M, Bernacki RJ. Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Res 24(2A):409-415, 2004
Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 10(7):2561-2569, 2004
Clark JA, Black AR, Leontieva OV, Frey MR, Pysz MA, Kunneva L, Woloszynska-Read A, Roy D, Black JD. Involvement of the ERK signaling cascade in protein kinase C-mediated cell cycle arrest in intestinal epithelial cells. J Biol Chem 279:9233-9247, 2004
Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, Beck A, Tan D. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol 17(4):430-439, 2004
Dong Y, Lee SO, Zhang H, Marshall J, Gao AC and Ip C. Prostate specific antigen (PSA) expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 64(1):19-22, 2004
Dziegielewska B, Kowalski D, Beerman T. SV40 DNA Replication Inhibition By the Monofunctional DNA Alkylator Et743. Biochemistry 43:14228-14237, 2004
El-Araby ME, Bernacki RJ, Makara GM, Pera PJ, Anderson WK. Synthesis, molecular modeling, and evaluation of nonphenolic indole analogs of mycophenolic acid. Bioorg Med Chem. 12(11):2867-2879, 2004
Frey MR, Clark JA, Bateman NW, Kazanietz MG, Black AR, Black JD. Cell cycle and protein kinase C-specific effects of resiniferatoxin and resiniferonol 9,13,14-orthophenyl acetate in intestinal epithelial cells.. Biochem. Pharmacol. 67(10):1873-1886, 2004
Gangjee A, Jain HD, McGuire JJ, Chu E, Kisliuk RL. Effect of an electron-withdrawing 3-fluoro in a classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine on the thymidylate synthase inhibitory activity and binding to TS mRNA. Pterins, Folates and Meurotransmitters in Molecular Medicine 2:184-187, 2004
Gangjee A, Jain HD, McGuire JJ, Kisliuk RL. Benzoyl ring halogenated classical 2-amino-6-methyl–3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]-pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents. J. Med. Chem. 47(27):6730-6739, 2004
Gangjee A, Zeng Y, McGuire JJ, Mehraein F, Kisliuk RL. Synthesis of classical, three carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates. J. Med. Chem. 47(27):6893-6901, 2004
Geng XD, Geney R, Pera P, Bernacki RJ, Ojima I. Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton. Bioorg Med Chem Lett 14(13):3491-3494, 2004
Ghosh D. Mutations in X-linked ichthyosis disrupt the active site structure of Estrone/DHEA sulfatase. Biochim. Biophys. Acta 1739, 1-4, 2004
Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kisiel N, Diegelman P, Chen Y, Pendyala L. Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol Cancer Ther 3(7):813-822, 2004
Jackson JG, St.Clair P, Sliwkowski MX, Brattain MG. Blockage of Epidermal Growth Factor- or heregulin dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res. 64:2601-2609, 2004
James TA, Sheldon DG, Rajput A, Kuvshinoff B, Javle M, Nava HR, Smith JL, Gibbs J. Risk factors associated with earlier age of onset for familial pancreatic cancer. Cancer 101 (12):2722-2726, 2004
Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine. Mol Pharmacol 65:18-27, 2004
Kee K, Foster BA, Merali S, Kramer DL, Hensen ML, Diegelman P, Kisiel N, Vujcic S, Mazurchuk R, Porter CW. Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice. J Biol Chem 279(79):40076-40083, 2004
Kee K, Vujcic S, Merali S, Diegelman P, Kisiel N, Powell CT, Kramer DL, Porter CW. Metabolic and antiproliferatiave consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells. J Biol Chem 279(26):27050-27058, 2004
Lala P, Higashiyama T, Erman M, Griswold J, Wagner T, Osawa Y, Ghosh D. Suppression of human Cytochrome P450 aromatase activity by monoclonal and recombinant antibody fragments and identification of a stable antigenic complex . J Steroid Biochem Mol Biol 88(3):235-245, 2004
Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60(4):303-309, 2004
Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 60(3):178-186, 2004
Lee JE, Settembre EC, Cornell KA, Riscoe MK, Sufrin JR, Ealick SE, Howell PL. Structural comparison of MTA phosphorylase and MTA/AdoHcy nucleosidase explains substrate preferences and identifies regions exploitable for inhibitor design. Biochemistry 43(18):5159-5169, 2004
Leontieva OV, Black JD. Identification of two distinct pathways of PKC á downregulation in intestinal epithelial cells. J Biol Chem 279:5788-5801, 2004
Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol (taxane paclitaxel) is an early event and independent on taxol-mediated mitotic arrest. J Biol Chem 279(15):15196-15203, 2004
Ling X, Li F. Silencing of antiapoptotic protein survivin expression by multiple approaches of RNA interference (RNAi) technology. Biotechniques 36(3):450-460, 2004
Mason DX, Jackson TJ, Lin AW. Molecular signature of oncogenic Ras-induced senescence. Oncogene 23:9238-9246, 2004
Masso-Welch PA, Zangani D, Ip C, Vaughan MM, Shoemaker S, McGee SO, Ip MM. Isomers of conjugated linoleic acid (CLA) differ in their effects on angiogenesis and survival of mammary adipose vasculature. J. Nutrition 134(2):299-307, 2004
McCann SE, Ip C, Ip MM, McGuire MK, Muti P, Edge SB, Trevisan M, Freudenheim JL. Dietary intake of conjugated linoleic acid and risk of pre- and postmenopausal breast cancer, Western New York Exposures and Breast Cancer Study. Cancer Epidemiology, Biomarkers & Prevention 13:1-5, 2004
Mihich E. Cancer therapeutics: personal experiences and future perspectives. Cancer Biol Ther. 3(9):911-915, 2004
Mihich E, Kaelin W. Fifteenth Annual Pezcoller Symposium: Molecular in Vivo Visualization of Cancer Cells. Cancer Res. 64(8):2929-2933, 2004
Minderman H, Brooks T, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR. Broad spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives orataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother Pharmacol 53(5):363-369, 2004
Muindi JR, Modzelewski RA, Peng Y, Hershberger PA, Trump DL, Johnson CS. Plasma 1alpha, 25-dihydroxycholecalciferol pharmacokinetics n normal and tumor bearing mice. Oncology 66(1):62-66, 2004
Mulhall JP, Martin DJ, Lubrano T, Moser M, Kwon E, Wojcik E, Shankey TV. Peyronie’s disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int J Impot Res. 16(2):99-104. 2004
Narayan S, Jaiswal AS, Kang D, Srivastava P, Das GM, Gairola CG. Cigarette smoke condensate-induced transformation of normal human breast epithelial cells in vitro. Oncogene 23(35):5880-5889, 2004
Posner GH, McRiner AJ, Paik IH, Sur S, Borstnik K, Xie S, Shapiro TA, Alagbala A, Foster BA. Anticancer and Antimalarial Efficacy and Safety of Artemisinin-Derived Trioxane Dimers in Rodents. J Med Chem. 47(5):1299-1301, 2004
Ramanathan R, Hwang JJ, Zamboni WC, Sinicrope F, Finkelstein S, Safran H, Wong MK, Earl M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. Low overexpression of HER-2/PPPneu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II Trial. Cancer Invest. 22(6): 858-865. 2004
Ramnath N, Hamm J, Schwartz G, Holden S, Eckhardt SG, Vredenburg MR, Bernacki RJ, Kaidbey J, Lathhia C, Kanter P, Creaven PJ. A phase I and pharmacokinetic study of BAY 59-8862: A novel taxane. Oncology 67(2):123-129, 2004.
Rustum YM. Thymidylate synthase: a critical target in cancer therapy? Front Biosci. 9:2467-2473, 2004
Sawhney RS, Cookson MM, Sharma B, Hauser J, Brattain MG. Autocrine TGFá regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 Kinase in colon cancer cells. J Biol Chem. 279(45):47379-47390, 2004
Sugiyama T, Ohno S, Ghosh D, Nakajin S. Alpha/beta,20beta-Hydroxysteroid dehydrogenase also has a cysteine residue that is involved in binding of cofactor NADPH. J Steroid Biochem Mol Biol 88(4-5):393-398, 2004
Tan DF, Wiseman S, Zhou YT, Li Q, Ward P, Slocum HK, Alrawi S, Loree T, Hicks W, Rigual N, Anderson G, Stoler D. Definition of a region of loss of heterozygosity at chromosome 11q23.3-25 in head and neck squamous cell carcinoma using laser capture microdissection technique. Diagn Mol Pathol 13(1):33-40, 2004
Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS. Anti Tumor activity of calcitriol: pre clinical and clinical studies. J Steroid Biochem Mol Biol 89:519-526, 2004
Tu CH, Melendy T, Beerman TA. DNA damage responses triggered by a highly cytotoxic monofunctional DNA alkylator, Hedamycin, a pluramycin anti-tumor antibiotic. Mol Cancer Ther 3:577-585, 2004
Wang J, Sergina N, Ko TC, Gong J, Brattain MG. Autocrine and exogenous transforming growth factor b control cell cycle inhibition through pathways with different sensitivity. J. Biol Chem 279(38):40237-40244, 2004
Wilkinson N, Black JD, Roukhadze E, Driscoll D, Smiley S, Hisakasu H, Geradts J, Brattain M. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 8(4):448-453, 2004
Xiao D, Choi S, Johnson DE, Voegl VG, Johnson CS, Trump DL, Lee YJ, Singh SV. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene 23(33):5594-5606, 2004
Xiao D, Johnson CS, Trump DL, Singh SV. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl Isothiocyanate-induced G2/M phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther 3(5):567-575, 2004
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23(20):3550-3560, 2004
Yang L, Cao Z, Li F, Post DE, Van Meir EG, Zhong H, Wood WC. Tumor-specific gene expression using susrvivin promoter is further increased by hypoxia. Gene Ther 11(15):1215-1223, 2004
Yin MB, Li ZR, Cao S, Durrani FA, Azrak RG, Frank C, Rustum YM. Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression. Mol Pharmacol 66:153-160, 2004
Zanker KS, Mihich E. Meeting Report: International symposium on emerging perspectives in clinical cancer research (Cape Town, South Africa 11/26-29, 2003). J. Cancer Res Clin Oncol 130:491-495, 2004
Zhang H, Zhang H, Lee L, Ip MM. The LIP isoform of C/EBPb, but not NFkB, mediates the transcriptional inhibition of b-casein by tumor necrosis factor-a (TNF). Endocrinology 145:2833-2844, 2004
Zhu N, Gu L, Findley HW, Li F, Zhou M. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23(45):7545-7551, 2004
Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath III CA, Barker S, Yamaoto M, Li F, Alvarez RD Curiel DT. Transcriptional Targeting of Tumors with a Novel Tumor-Specific Survivin Promoter. Cancer Gene Ther 11(4):256-262, 2004


